(Reuters) - Increased manufacturing capacity for Eli Lilly's highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by $3 billion on Thursday ...

Wegovy Q3 sales total $2.5 bln Beat forecast ... a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug ...

Novo Nordisk blamed its lower sales forecast on competition from copycat versions of its anti-obesity drugs in the United ... its blockbuster diabetes and weight-loss treatments Ozempic and ...

Driving the news: The Indianapolis-based drug giant raised its sales forecast after crushing revenue expectations for its most critical treatments. Sales of weight-loss drug Zepbound totaled $1.24 ...

global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating more than a 38% increase from its prior forecast. The company’s CEO Albert Bourla has said the ...

Eli Lilly raised its sales forecast for the year by $3 billion on improved manufacturing and increased supplies of its weight loss drug. REUTERS Weight-loss drugs have even become a trend among ...

But a new class of weight-loss drugs that help people ... 80% probability of success as a commercial drug. The firm forecasts that annual global sales of VK2735 will reach $11.7 billion in 2040.

Increased manufacturing capacity for Eli Lilly's highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by US$3-billion on Aug. 8 - and its shares ...

COPENHAGEN (Reuters) - Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it ...

Eli Lilly raised its annual sales forecast by $3 billion on Thursday, driven by surging demand and ramped up manufacturing capacity for its popular weight-loss drug Zepbound, lifting its shares ...

London: Eli Lilly raised its annual sales forecast by $3 billion on Thursday, driven by surging demand and ramped up manufacturing capacity for its popular weight-loss drug Zepbound, lifting its ...